From Diagnosis to Treatment - Part 3 of 4, Diagnosis of Breast Cancer with H&E and Immunohistochemistry Stains
In the case of Breast Cancer, the patient’s cancer is usually detected by a mammogram or palpitation of an experienced Physician. However, these first indications that something is wrong must be confirmed by a more scientific approach. Usually what follows is an actual biopsy; a sample of the tissue in question is removed from the person. Once a tumor is confirmed from the biopsy, then a more radical surgical approach may be necessary or other treatments are performed. Part 3 of the series addresses the importance of proper H&E/ICH sections and staining for diagnosis of breast tumors. A view of optimization and controls for prognostic markers will be examined, and brief overview of IHC diagnosis and treatment will presented.
Learning Objectives
Discuss the importance of good H&E / IHC sections, and differences in the pathologist’s evaluation of core versus whole-section specimens.
- Understand the differential diagnosis of types of breast tumors.
- To view a good optimization of the antibody as an essential part of laboratory practice.
- Examine a variety of controls for prognostic (graded) IHC markers such as ER/PR/ HER2 .
- A brief overview of the next steps after IHC diagnosis and treatment.
About the presenter
Dr. Thomas Haas is an attending Pathologist and Director of Molecular Pathology at Mercy Health Systems, Janesville, Wisconsin. He received his Doctor of Osteopathic Medicine from Des Moines University. His daily responsibilities involve anatomic, cytologic, and clinical pathology in a community hospital and system reference laboratory, with participation in tumor board and medical education conferences. His areas of interest include the development of immunohistochemistry panels for tumor diagnosis, molecular pathology, and histotechnology education for the National Society for Histotechnology (NSH). Dr. Haas is board certified in Anatomic and Clinical Pathology.
El contenido de Leica Biosystems Knowledge Pathway está sujeto a las condiciones de uso del sitio web de Leica Biosystems, disponibles en: Aviso legal.. El contenido, incluidos los webinars o seminarios web, los recursos de formación y los materiales relacionados, está destinado a proporcionar información general sobre temas concretos de interés para los profesionales de la salud y no está destinado a ser, ni debe interpretarse como asesoramiento médico, normativo o jurídico. Los puntos de vista y opiniones expresados en cualquier contenido de terceros reflejan los puntos de vista y opiniones personales de los ponentes/autores y no representan ni reflejan necesariamente los puntos de vista ni opiniones de Leica Biosystems, sus empleados o sus agentes. Cualquier enlace incluido en el contenido que proporcione acceso a recursos o contenido de terceros se proporciona únicamente por comodidad.
Para el uso de cualquier producto, debe consultarse la documentación correspondiente del producto, incluidas las guías de información, los prospectos y los manuales de funcionamiento.
Copyright © 2024 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.